{"gene":"RHOC","run_date":"2026-06-10T06:43:36","timeline":{"discoveries":[{"year":1989,"finding":"RhoC protein is ADP-ribosylated by Clostridium botulinum exoenzyme C3, and C3 treatment of Vero cells causes disappearance of actin microfilaments and actinomorphic shape changes, establishing that a rho protein (RhoC) regulates actin microfilament assembly.","method":"Bacterial expression of human rhoC gene product, in vitro ADP-ribosylation assay, cell treatment with C3 exoenzyme and morphological analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct biochemical assay (ADP-ribosylation) combined with cell biological readout (microfilament disassembly), foundational paper replicated in many subsequent studies","pmids":["2501082"],"is_preprint":false},{"year":2000,"finding":"Overexpression of RhoC in melanoma cells enhances metastasis and invasion, while dominant-negative Rho inhibits metastasis, establishing RhoC as a functional driver of tumor cell invasion in vivo.","method":"In vivo selection of metastatic melanoma cells, DNA microarray gene expression analysis, overexpression and dominant-negative constructs, in vivo metastasis assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal gain- and loss-of-function in vivo, replicated across subsequent studies in multiple cancer types","pmids":["10952316"],"is_preprint":false},{"year":2000,"finding":"RhoC GTPase overexpression in human mammary epithelial cells increases production of angiogenic factors (VEGF, bFGF, IL-6, IL-8); inhibition of RhoC with C3 exotransferase decreases angiogenic factor production, directly linking RhoC activity to angiogenic signaling.","method":"Stable transfection of RhoC in HME cells, ELISA measurement of conditioned media, C3 exotransferase inhibition","journal":"Neoplasia (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 / Moderate — orthogonal gain-of-function and pharmacological inhibition, quantitative ELISA readout, single lab","pmids":["11191108"],"is_preprint":false},{"year":2002,"finding":"XPLN, a guanine nucleotide exchange factor, stimulates GDP/GTP exchange on RhoA and RhoB but NOT RhoC in vitro; the inability to activate RhoC is determined by isoleucine 43 in RhoC (a position occupied by valine in RhoA and RhoB), establishing a structural basis for GEF selectivity among Rho isoforms.","method":"In vitro nucleotide exchange assays, preferential binding assays, site-specific mutagenesis (Ile43 in RhoC), cellular stress fiber/focal adhesion assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro exchange assay with mutagenesis identifying the specific residue, single lab but multiple orthogonal methods","pmids":["12221096"],"is_preprint":false},{"year":2002,"finding":"Activation of the MAPK pathway downstream of RhoC GTPase is responsible for motility, invasion, and production of angiogenic factors in inflammatory breast cancer cells, while PI3K pathway activation drives anchorage-independent growth.","method":"Pharmacological inhibitors of MAPK and PI3K pathways in HME-RhoC transfectants and SUM149 IBC cells; motility, invasion, and angiogenesis assays","journal":"Clinical & experimental metastasis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection with defined functional readouts, single lab","pmids":["12090470"],"is_preprint":false},{"year":2003,"finding":"Atorvastatin prevents geranylgeranylation (isoprenylation) of RhoC, inhibiting its subcellular localization and activity, and blocks melanoma cell invasion in vitro and in vivo metastasis of RhoC-overexpressing cells, establishing that RhoC biological activity depends on posttranslational geranylgeranylation.","method":"HMG-CoA reductase inhibitor treatment, subcellular fractionation and Rho activity assays, in vitro invasion assays, in vivo melanoma metastasis model","journal":"Molecular cancer therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition with mechanistic localization assay and in vivo validation, single lab","pmids":["14578459"],"is_preprint":false},{"year":2004,"finding":"RhoC stimulates invasion but not proliferation in invasive breast carcinoma (SUM-159) cells; RhoA impedes invasion; a compensatory relationship exists between RhoA and RhoC expression/activation levels, and RhoC depletion inversely affects Rac1 activation.","method":"Stable retroviral RNAi knockdown of RhoA or RhoC, invasion assays, Rho and Rac1 activity measurements","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — selective RNAi knockdown with defined functional readouts, single lab","pmids":["15574779"],"is_preprint":false},{"year":2004,"finding":"In orthotopic lung cancer mouse model, RhoC overexpression enhances metastasis and increases MMP-2 activity, while dominant-negative Rho suppresses both, without affecting primary tumor growth; establishing RhoC as a promoter of metastasis through MMP upregulation.","method":"Retroviral transduction of RhoC or dominant-negative Rho into murine lung cancer cells, orthotopic intrapulmonary inoculation, RT-PCR and gelatin zymography for MMPs","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo model with mechanistic MMP analysis, single lab","pmids":["14871999"],"is_preprint":false},{"year":2004,"finding":"Loss of WISP3 in HME cells increases RhoC mRNA and protein levels, while restoration of WISP3 in IBC cells decreases RhoC protein, indicating that WISP3 modulates RhoC expression and the two genes cooperate in the IBC phenotype.","method":"Antisense inhibition of WISP3, RT-PCR and Western blot for RhoC, VEGF ELISA, soft agar growth assays","journal":"Breast cancer research : BCR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal gain- and loss-of-function, single lab","pmids":["14696649"],"is_preprint":false},{"year":2005,"finding":"RhoC-deficient mice (RhoC knockout) are viable and fertile; loss of RhoC does not affect tumor development but decreases tumor cell motility and metastatic cell survival, leading to drastic inhibition of metastasis, establishing RhoC as specifically required for metastasis but dispensable for embryogenesis and tumor initiation.","method":"RhoC knockout mouse generation, tumor induction models, cell motility and survival assays, metastasis quantification","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic knockout with multiple phenotypic readouts, defines the in vivo requirement of RhoC for metastasis","pmids":["16107613"],"is_preprint":false},{"year":2006,"finding":"RhoC is required for invasion but not random motility in PC-3 prostate cancer cells; inhibition of RhoC with C3 exotransferase or dominant-negative RhoC promotes IGF-I-stimulated random motility but decreases invasion and experimental metastasis, and causes alterations in focal adhesion protein distribution.","method":"C3 exotransferase pharmacological inhibition and dominant-negative RhoC overexpression, chemotaxis chamber assays, in vivo experimental metastasis, immunofluorescence of focal adhesion proteins","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two inhibitory approaches with defined mechanistic readouts, single lab","pmids":["16314838"],"is_preprint":false},{"year":2006,"finding":"PKCε knockdown in HNSCC cells reduces active and serine-phosphorylated RhoA and RhoC; constitutively active RhoC rescues invasion and partially rescues motility in PKCε-deficient cells, establishing RhoC as a downstream effector of PKCε, possibly through direct post-translational phosphorylation.","method":"siRNA knockdown of PKCε, constitutively active RhoC rescue experiments, invasion and motility assays, Western blot for phospho-RhoC/RhoA","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi + rescue epistasis, single lab","pmids":["17018591"],"is_preprint":false},{"year":2008,"finding":"RhoC promotes prostate cancer metastasis via sequential activation of Pyk2, FAK, MAPK, and Akt, followed by upregulation of MMP2 and MMP9; inhibition of Pyk2 blocks RhoC-dependent activation of FAK, MAPK, and Akt and suppresses MMP activity.","method":"RhoC overexpression in prostate cancer cells, antibody array for signaling molecules, Pyk2 kinase inhibitor treatment, in vitro invasion/motility assays, in vivo metastasis model","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — signaling pathway dissection with pharmacological inhibitors and defined readouts, single lab","pmids":["18794150"],"is_preprint":false},{"year":2010,"finding":"Formin-like 2 (FMNL2) is a specific effector of RhoC but not RhoA or RhoB; FMNL2 shows selective interaction with active RhoC, and RhoC regulates FMNL2 autoinhibition; suppression of FMNL2 inhibits RhoC-dependent but not RhoA-dependent rounded invasive cell migration.","method":"siRNA-based screen of all 15 human formins in 3D cell motility, selective pulldown with active GTPase forms, knockdown rescue experiments in cancer cell lines","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic siRNA screen plus selective protein interaction assays, epistasis in 3D invasion, multiple cell lines","pmids":["20101212"],"is_preprint":false},{"year":2010,"finding":"HA-induced CD44 interaction with c-Src kinase activates Twist, which drives miR-10b transcription; miR-10b suppresses HOXD10, leading to RhoA/RhoC upregulation and ROCK activation, resulting in breast tumor cell invasion. This pathway is abrogated by c-Src inhibition, Twist siRNA, or anti-miR-10b inhibitor.","method":"ChIP assays for Twist at miR-10b promoter, siRNA and inhibitor experiments, Western blot for RhoC/RhoA/ROK, invasion assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and multiple orthogonal interventions in a single cell line system, single lab","pmids":["20843787"],"is_preprint":false},{"year":2011,"finding":"RhoC activity is spatially confined to areas surrounding invadopodia, regulated by p190RhoGEF (which localizes around invadopodia to activate RhoC) and p190RhoGAP (which localizes inside invadopodia to deactivate RhoC); RhoC activation surrounding invadopodia enhances cofilin phosphorylation outside the structure, restricting cofilin-mediated actin barbed end generation to within the invadopodium core.","method":"Live-cell imaging with fluorescent RhoC FLARE biosensor, immunofluorescence localization of p190RhoGEF and p190RhoGAP, cofilin phosphorylation assays","journal":"Current biology : CB","confidence":"High","confidence_rationale":"Tier 2 / Strong — live biosensor imaging combined with spatial localization and biochemical readouts, establishes mechanism at subcellular resolution","pmids":["21474314"],"is_preprint":false},{"year":2011,"finding":"RhoC depletion increases cell spreading and induces Rac1 activation around the cell periphery in broad lamellipodia, inhibiting directed migration and invasion; these effects are mediated by formin FMNL3, identified as a new effector of RhoC but not RhoA; RhoA acts through ROCK1/ROCK2 to regulate migratory polarity.","method":"RNAi knockdown of RhoA and RhoC, 2D and 3D migration/invasion assays, Rac1 activity measurements, FMNL3 knockdown rescue epistasis","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal RNAi with multiple rescue and epistasis experiments, two orthogonal 2D/3D assays, identifies FMNL3 as RhoC-specific effector","pmids":["21576392"],"is_preprint":false},{"year":2011,"finding":"p38γ MAPK regulates RhoC expression by modulating RhoC ubiquitination; p38γ knockdown reduces RhoC protein levels and inhibits breast cancer cell motility and metastasis.","method":"p38γ knockdown, Western blot for RhoC, ubiquitination assay, motility assays, computational cell mechanics model, clinical specimen correlation","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic ubiquitination assay plus KD functional readout, single lab","pmids":["21862636"],"is_preprint":false},{"year":2011,"finding":"PKN3 physically interacts preferentially with RhoC over other Rho GTPases; PKN3 catalytic activity is increased in the presence of Rho GTPases; the PKN3-RhoC complex is co-expressed in late-stage malignancies and contributes to tumor invasion and metastasis.","method":"Co-immunoprecipitation, in vitro kinase activity assay with Rho GTPases, orthotopic mouse tumor models with PKN3 knockdown","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus in vitro kinase assay, single lab","pmids":["22217540"],"is_preprint":false},{"year":2011,"finding":"SmgGDS exclusively activates RhoA and RhoC (not other tested GTPases) in vitro; this specificity is catalytic and requires the polybasic region of RhoA for activation; SmgGDS uses a distinct exchange mechanism from canonical GEFs. This specificity is retained in cells.","method":"In vitro nucleotide exchange assays on a large panel of purified GTPases, mutagenesis of SmgGDS and RhoA, preferential nucleotide-depleted state binding assay, cellular GEF activity assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with large GTPase panel, mutagenesis, mechanistic characterization, and cellular validation","pmids":["21242305"],"is_preprint":false},{"year":2011,"finding":"RhoC and IQGAP1 bind to each other (co-immunoprecipitation); RhoC stimulates migration of gastric cancer cells through IQGAP1 as a downstream effector; knockdown of IQGAP1 blocks RhoC-induced migration stimulation.","method":"Co-immunoprecipitation, siRNA knockdown of RhoC and IQGAP1, constitutively active RhoC overexpression, transwell migration assay","journal":"Molecular medicine reports","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP plus epistatic knockdown rescue, single lab","pmids":["21537845"],"is_preprint":false},{"year":2011,"finding":"RhoGDIα-mediated balance between RhoA and RhoC controls invasive phenotype; RhoC silencing increases expression of tumor suppressor NAG-1 and reduces migration and anchorage-independent growth; this occurs indirectly through upregulation of RhoA via competition for RhoGDIα.","method":"siRNA knockdown of RhoC, RhoA, and RhoGDIα, RhoA mutant unable to bind RhoGDIα, gene expression profiling, migration and soft agar assays, in vivo tumor growth","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple siRNA knockdowns with rescue epistasis, defined molecular mechanism through RhoGDIα competition, single lab","pmids":["21757538"],"is_preprint":false},{"year":2012,"finding":"Akt1 directly phosphorylates RhoC GTPase, and this phosphorylation is absolutely essential for IBC cell invasion; Akt3 (not Akt1) regulates IBC cell survival; PI3K/Akt1/RhoC pathway is specifically upregulated in IBC patients.","method":"In vitro Akt1 kinase assay with RhoC substrate, phospho-specific detection, siRNA knockdown of Akt isoforms, invasion assays, clinical IBC specimen analysis","journal":"Molecular cancer research : MCR","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay demonstrating direct phosphorylation plus functional rescue experiments, single lab with clinical correlation","pmids":["22896661"],"is_preprint":false},{"year":2012,"finding":"RhoC and IQGAP1 bind each other; RhoC stimulates gastric cancer cell proliferation through IQGAP1 by increasing cyclin E and cyclin D1 levels; IQGAP1 knockdown blocks RhoC-induced proliferation but not vice versa, defining IQGAP1 as a downstream effector of RhoC in proliferation.","method":"Co-immunoprecipitation, immunofluorescence co-localization, siRNA knockdown, constitutively active RhoC overexpression, MTT and BrdU proliferation assays, Western blot for cyclins","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, co-localization, and epistatic knockdown with defined molecular readouts, single lab","pmids":["23145020"],"is_preprint":false},{"year":2013,"finding":"A RhoC FLARE biosensor revealed that RhoC activity is higher than RhoA in regions distal from the cell edge during protrusion; RhoC activation precedes RhoA activation distally before edge protrusion; p190RhoGEF and p190RhoGAP regulate actin barbed end distribution and protrusion directionality through RhoC activity balance.","method":"FRET-based RhoC FLARE biosensor live imaging, comparison with RhoA biosensor, computational analysis of spatio-temporal GTPase activity during protrusion/retraction and macropinocytosis","journal":"PloS one / Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Strong — validated biosensor with live imaging and computational analysis, comparison across two isoforms with two independent labs using similar approaches","pmids":["24224016","23704350"],"is_preprint":false},{"year":2010,"finding":"RhoC promotes vascular homeostasis in endothelial cells: it stimulates proliferation by stabilizing nuclear β-catenin (promoting cyclin D1 transcription); negatively regulates migration through MAPKs/MLC2 signaling; and decreases vascular permeability through downregulation of PLCγ-Ca2+-eNOS cascade. RhoC morpholino in zebrafish increases vascular permeability.","method":"HUVEC siRNA/overexpression experiments, Western blot for β-catenin/cyclin D1/MLC2/eNOS, permeability assays, zebrafish RhoC morpholino model","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple mechanistic readouts in endothelial cells plus in vivo zebrafish validation, single lab","pmids":["26136364"],"is_preprint":false},{"year":2006,"finding":"RhoC promotes melanoma invasion through a PI3K/Akt pathway independent of ROCK signaling; RhoC overexpression increases phospho-Akt (Ser473); inhibition of PI3K or Akt (but not ROCK) decreases pAkt levels; both ROCK and PI3K/Akt pathways contribute independently to RhoC-driven invasion.","method":"Stable RhoC overexpression in melanoma cells, C3 transferase inhibition, PI3K/Akt/ROCK pharmacological inhibitors, Western blot for pAkt, invasion assays","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection of parallel pathways with mechanistic readouts, single lab","pmids":["16470169"],"is_preprint":false},{"year":2010,"finding":"RhoC (but not RhoA) modulates surface expression and colocalization of α2 and β1 integrins in MDA-MB-231 cells on collagen I, establishing a specific role for RhoC in cell-matrix adhesion through integrin regulation.","method":"Selective siRNA knockdown of RHOC vs RHOA, flow cytometry and immunofluorescence for integrin surface expression, collagen I and Matrigel invasion/adhesion assays","journal":"Cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-selective RNAi with specific integrin readout, single lab","pmids":["20503409"],"is_preprint":false},{"year":2013,"finding":"ARHGAP21 functions as a RhoGAP with enzymatic activity toward both RhoA and RhoC; its depletion in PC3 prostate cancer cells decreases proliferation and increases migration.","method":"In vitro GAP activity assay for RhoA and RhoC, siRNA knockdown in LNCaP and PC3 cells, proliferation and migration assays","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro GAP assay defining substrate specificity, plus functional cellular KD, single lab","pmids":["23200924"],"is_preprint":false},{"year":2009,"finding":"RhoC has higher intrinsic GTP binding affinity, faster intrinsic and GEF-stimulated GDP/GTP exchange rates than RhoA; RhoC is predominantly localized in the membrane-containing fraction whereas RhoA is mainly cytoplasmic; these biochemical differences are not due to differential RhoGDI interaction and correlate with RhoC-specific enhancement of migration and invasion in pancreatic carcinoma cells.","method":"In vitro GTP/GDP binding and exchange assays, subcellular fractionation, RhoGDI interaction assays, serum-response factor reporter assays, migration and invasion assays","journal":"Biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical assays with subcellular fractionation and functional validation, rigorous mechanistic characterization, single lab","pmids":["19642867"],"is_preprint":false},{"year":2013,"finding":"Differential binding affinities of PRK isoforms (PRK1, PRK2, PRK3) for RhoA, RhoB, and RhoC were measured; RhoA and RhoC bind PRK1 HR1a domain with similar affinities; PRK2 and PRK3 domains bind all Rho isoforms less well than PRK1; establishing quantitative interaction parameters for RhoC-PRK signaling.","method":"In vitro binding/affinity assays using purified HR1 domain constructs and purified Rho GTPases, thermal stability analysis","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with quantitative binding measurements, single lab","pmids":["24128008"],"is_preprint":false},{"year":2010,"finding":"p53 directly transcriptionally activates RhoC and LIMK2 expression in response to genotoxic agents; LIMK2 activation downstream of RhoC has a pro-survival function following DNA damage; LIMK inhibition sensitizes cells to radio- or chemotherapy.","method":"ChIP (implied by 'direct p53 target genes'), siRNA knockdown of LIMK2, pharmacological LIMK inhibition, genotoxic agent treatment, cell survival assays","journal":"Cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — p53 target gene identification with functional downstream analysis, single lab","pmids":["21079653"],"is_preprint":false},{"year":2011,"finding":"Notch1 signaling regulates RhoC activity in cervical carcinoma; Notch1 inhibition with DAPT decreases RhoC activity; constitutively active RhoC rescues the phenotypic effects of Notch1 inactivation on invasion, migration, and anoikis resistance, placing RhoC as an effector of Notch1.","method":"Pharmacological Notch1 inhibition with DAPT, Rho activity assay (G-LISA), constitutively active RhoC rescue experiments, invasion/migration/anoikis assays","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition plus constitutively active rescue epistasis, single lab","pmids":["19953094"],"is_preprint":false},{"year":2012,"finding":"miR-493 decreases RhoC 3'UTR luciferase activity and protein expression in bladder cancer cells, and decreases RhoC-ROCK1 binding, thereby reducing cell motility and migration.","method":"miR-493 transfection, 3'UTR luciferase reporter assay, Western blot for RhoC, co-immunoprecipitation for RhoC-ROCK1 interaction, migration assays","journal":"Molecular cancer therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase 3'UTR assay plus Co-IP for RhoC-ROCK1, single lab","pmids":["22057916"],"is_preprint":false},{"year":2017,"finding":"HIF-3α promotes pancreatic cancer invasion by transcriptionally activating the RhoC-ROCK1 signaling pathway under hypoxic and normoxic conditions; HIF-3α overexpression stimulates F-actin polymerization.","method":"HIF-3α knockdown and overexpression, ChIP/transcriptional reporter assays for RhoC promoter (implied), invasion/migration assays, F-actin staining, in vivo xenograft","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptional regulation assay with gain/loss of function and functional readouts, single lab","pmids":["28928287"],"is_preprint":false},{"year":2017,"finding":"RhoD recruits PAK6 to the plasma membrane to antagonize RhoC signaling and suppress RhoC-dependent cell contraction and blebbing; vaccinia virus F11 protein inhibits RhoD, thereby relieving PAK6 suppression of RhoC and enabling ROCK-mediated cell contraction specifically through RhoC (not RhoA).","method":"Vaccinia infection model, RhoC/RhoD/PAK6 knockdowns, localization studies, ROCK inhibition, genetic epistasis with constitutively active/dominant-negative constructs","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic epistasis experiments establishing the RhoD-PAK6-RhoC signaling axis, mechanistic dissection in viral infection context and normal cells","pmids":["28486133"],"is_preprint":false},{"year":2015,"finding":"RhoC depletion by RNAi reduces PC3 prostate cancer cell adhesion to endothelial cells, intercalation between endothelial cells, and transendothelial migration in vitro; ROCK1 and ROCK2 depletion similarly decreases cancer-endothelial interactions; RhoC depletion reduces early lung retention and experimental metastasis in vivo.","method":"RNAi depletion of RhoC, ROCK1, ROCK2; adhesion, intercalation, transendothelial migration assays; in vivo lung retention and metastasis experiments","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple RNAi knockdowns with in vitro and in vivo functional readouts, single lab","pmids":["25677806"],"is_preprint":false},{"year":2019,"finding":"RhoC promotes radioresistance in cervical cancer via ROCK2, which interacts with DNA repair pathway proteins (pH2Ax, MRE11, RAD50); ROCK2 inhibition reduces expression of pH2Ax and MRN complex proteins, and abolishes RhoC-conferred radioresistance, establishing RhoC-ROCK2 as a regulator of the DNA repair machinery.","method":"RhoC overexpression/siRNA, ROCK2 inhibition/siRNA, immunofluorescence for DNA repair markers, transcriptomic profiling, radiation survival assays, clinical sample analysis","journal":"Journal of experimental & clinical cancer research : CR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic connection via transcriptomics and immunofluorescence with functional rescue, single lab","pmids":["31488179"],"is_preprint":false},{"year":2020,"finding":"RNF180 E3 ubiquitin ligase directly binds RhoC and promotes its ubiquitination and proteasomal degradation; RhoC knockdown reduces STAT3 phosphorylation in gastric cancer cells, placing RhoC upstream of STAT3 activation.","method":"Co-immunoprecipitation for RNF180-RhoC interaction, ubiquitin label-free proteomics, RhoC shRNA knockdown, Western blot for STAT3 phosphorylation","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ubiquitination proteomics and functional phosphorylation readout, single lab","pmids":["33082325"],"is_preprint":false},{"year":2023,"finding":"BCAT1 directly interacts with RhoC, elevating RhoC activity; branched-chain α-keto acids (BCKA), derived from BCAA catabolism, directly bind RhoC and promote its activity; BCAT1E61A mutation confers higher enzymatic activity and boosts RhoC-dependent cell motility; candesartan inhibits BCAT1E61A activity and represses RhoC activity.","method":"Co-immunoprecipitation of BCAT1-RhoC, in vitro BCKA-RhoC binding assay, RhoC activity assays, BCAT1 knockout/rescue with BCAT1E61A, in vitro motility assays, in vivo peritoneal metastasis model","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro direct binding of BCKA to RhoC plus Co-IP of BCAT1-RhoC complex, functional rescue and in vivo validation, single lab but multiple orthogonal methods","pmids":["37337119"],"is_preprint":false},{"year":2019,"finding":"FMNL3 interacts directly with RhoC (demonstrated by Co-IP, immunofluorescence co-localization, and GST pull-down), acts as an effector of RhoC to activate the FAK/p-MAPK/p-AKT signaling pathway, and regulates RhoC-dependent remodeling of actin-based protrusions (filopodia and lamellipodia) to promote colorectal cancer cell invasion.","method":"Co-immunoprecipitation, immunofluorescence co-localization, GST pull-down assay, FAK/MAPK/AKT Western blot, pharmacological inhibitors (TAE226, U0126, LY294002), invasion/migration assays","journal":"World journal of gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — three independent protein interaction methods (Co-IP, co-localization, GST pull-down) plus pathway pharmacology, single lab","pmids":["30228782"],"is_preprint":false},{"year":2015,"finding":"RhoC regulates cancer stem cell (CSC) formation in HNSCC by promoting IL-6 secretion, which rescues STAT3 phosphorylation; RhoC knockdown decreases ALDH, CD44, and stem cell transcription factors (Nanog, Oct3/4, Sox2) and reduces STAT3 phosphorylation; IL-6 stimulation rescues STAT3 phosphorylation in RhoC knockdown lines.","method":"shRNA knockdown of RhoC, ALDH/CD44 flow cytometry, tumorsphere formation, IL-6 ELISA, Western blot for STAT3 phosphorylation, STAT3 overexpression rescue","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined epistatic pathway via IL-6/STAT3 rescue, single lab","pmids":["24533098"],"is_preprint":false},{"year":2015,"finding":"Caveolin-1 overexpression mediates IBC cell invasion through activation of Akt1, which phosphorylates RhoC GTPase; caveolin-1 siRNA knockdown decreases Akt1 activation and thereby decreases RhoC phosphorylation and IBC cell invasion.","method":"caveolin-1 siRNA and scaffolding domain inhibition, Western blot for Akt1 activation and RhoC phosphorylation, invasion assays","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic KD experiments linking caveolin-1 to Akt1-RhoC phosphorylation pathway, single lab","pmids":["25559359"],"is_preprint":false}],"current_model":"RhoC is a membrane-associated small GTPase that is activated by specific GEFs (including SmgGDS and p190RhoGEF) and inactivated by GAPs (including p190RhoGAP and ARHGAP21); it requires geranylgeranylation for membrane localization and biological activity; it acts through distinct effectors including formins FMNL2 and FMNL3, ROCK1/ROCK2, and IQGAP1 to reorganize the actin cytoskeleton, regulate cofilin phosphorylation at invadopodia, drive directional cell migration and invasion; upstream regulators include PKCε (via serine phosphorylation), Akt1 (direct phosphorylation required for invasion), p38γ (via ubiquitination control of RhoC stability), RNF180 (E3 ligase promoting RhoC degradation), and BCAT1-derived branched-chain α-keto acids (direct binding to activate RhoC); spatiotemporally, RhoC activity is confined to areas surrounding invadopodia by p190RhoGEF/p190RhoGAP, and is antagonized by the RhoD-PAK6 axis; physiologically, RhoC is dispensable for normal development but specifically required for metastasis, and also regulates angiogenic factor secretion, endothelial barrier function, cancer stem cell maintenance via IL-6/STAT3, and radioresistance via ROCK2/DNA repair machinery."},"narrative":{"mechanistic_narrative":"RhoC is a membrane-associated small GTPase that regulates actin cytoskeleton dynamics and is the principal Rho isoform driving tumor cell motility, invasion, and metastasis [PMID:2501082, PMID:10952316, PMID:16107613]. Genetic ablation establishes that RhoC is dispensable for embryogenesis and tumor initiation but specifically required for metastasis, acting on tumor cell motility and metastatic cell survival [PMID:16107613]. Biochemically RhoC is distinguished from RhoA by higher intrinsic GTP-binding affinity, faster exchange kinetics, and predominantly membrane localization, and its biological activity depends on geranylgeranylation for proper subcellular targeting [PMID:14578459, PMID:19642867]. RhoC cycling is governed by isoform-selective regulators: SmgGDS and p190RhoGEF activate it while p190RhoGAP and ARHGAP21 inactivate it, and a structural determinant (Ile43) excludes activation by the GEF XPLN [PMID:12221096, PMID:21474314, PMID:21242305, PMID:23200924]. Live-biosensor imaging shows RhoC activity is spatially confined to the rim surrounding invadopodia by reciprocal localization of p190RhoGEF and p190RhoGAP, restricting cofilin-mediated actin barbed-end generation to the invadopodium core and directing protrusion [PMID:21474314, PMID:24224016, PMID:23704350]. Downstream, RhoC signals through the RhoC-selective formin effectors FMNL2 and FMNL3, through ROCK1/ROCK2, and through IQGAP1 to remodel actin, control migratory polarity, and drive invasion and proliferation [PMID:20101212, PMID:21576392, PMID:21537845, PMID:23145020, PMID:30228782]. Upstream, RhoC is activated or stabilized by PKCε- and Akt1-mediated phosphorylation, by p38γ-controlled ubiquitination, and by direct binding of BCAT1 and branched-chain α-keto acids, while RNF180-mediated ubiquitination targets it for degradation [PMID:17018591, PMID:21862636, PMID:22896661, PMID:33082325, PMID:37337119]. Beyond cancer cell-autonomous invasion, RhoC promotes angiogenic factor secretion and MMP induction, endothelial barrier and proliferation homeostasis, cancer stem cell maintenance via IL-6/STAT3, and radioresistance via a ROCK2-DNA repair axis [PMID:11191108, PMID:14871999, PMID:26136364, PMID:31488179, PMID:24533098].","teleology":[{"year":1989,"claim":"Established that a Rho protein controls actin microfilament organization, the foundational activity later attributed to RhoC-driven cell shape change.","evidence":"In vitro C3 exoenzyme ADP-ribosylation of bacterially expressed RhoC plus microfilament/morphology readout in Vero cells","pmids":["2501082"],"confidence":"High","gaps":["C3 does not distinguish RhoC from other Rho isoforms","no isoform-specific effectors identified","no link to invasion or metastasis yet"]},{"year":2000,"claim":"Defined RhoC as a functional driver of tumor cell invasion and metastasis rather than a passive marker, and linked it to angiogenic factor production.","evidence":"Gain- and dominant-negative loss-of-function in melanoma and mammary epithelial cells with in vivo metastasis assays and ELISA for angiogenic factors","pmids":["10952316","11191108"],"confidence":"High","gaps":["dominant-negative Rho is not RhoC-selective","direct effectors mediating invasion unidentified","mechanism linking RhoC to angiogenic secretion unresolved"]},{"year":2002,"claim":"Showed that GEF activation of RhoC is isoform-selective and identified the structural determinant (Ile43) governing GEF discrimination among Rho isoforms.","evidence":"In vitro nucleotide exchange assays and site-directed mutagenesis comparing XPLN action on RhoA/B/C","pmids":["12221096"],"confidence":"High","gaps":["did not identify the physiological RhoC GEF","structural basis tested for one GEF only"]},{"year":2003,"claim":"Demonstrated that RhoC requires geranylgeranylation for membrane localization and biological activity, defining a druggable post-translational dependency.","evidence":"Atorvastatin (HMG-CoA reductase) inhibition with subcellular fractionation, Rho activity assays, and in vivo metastasis of RhoC-overexpressing cells","pmids":["14578459"],"confidence":"Medium","gaps":["statin effects not RhoC-specific","prenylation enzymes not directly perturbed","in vivo specificity for RhoC over RhoA limited"]},{"year":2004,"claim":"Distinguished RhoC from RhoA functionally, showing RhoC selectively promotes invasion (not proliferation) and that RhoA/RhoC and Rac1 are reciprocally balanced.","evidence":"Selective retroviral RNAi of RhoA vs RhoC with invasion assays and Rho/Rac activity measurements; orthotopic lung model linking RhoC to MMP-2","pmids":["15574779","14871999"],"confidence":"Medium","gaps":["molecular basis of RhoA/RhoC antagonism unresolved at this stage","effector mediating invasion not identified","single cell-line systems"]},{"year":2005,"claim":"Provided definitive in vivo genetics establishing RhoC as required for metastasis but dispensable for development and tumor initiation.","evidence":"RhoC knockout mouse with tumor induction, motility, survival, and metastasis quantification","pmids":["16107613"],"confidence":"High","gaps":["does not define the effector pathway responsible in vivo","potential compensation by RhoA not fully excluded"]},{"year":2006,"claim":"Dissected the downstream signaling branches, separating RhoC-driven invasion (ROCK-independent PI3K/Akt and FAK/MAPK) from random motility and from anchorage-independent growth.","evidence":"Pharmacological pathway dissection and dominant-negative/C3 inhibition in melanoma and prostate cancer cells with invasion/motility readouts","pmids":["16470169","16314838"],"confidence":"Medium","gaps":["pharmacological inhibitors lack isoform selectivity","direct RhoC-effector contacts not demonstrated"]},{"year":2010,"claim":"Identified RhoC-selective formin effectors (FMNL2, FMNL3) and isoform-specific roles in integrin regulation and endothelial homeostasis, explaining RhoC's distinct cytoskeletal output.","evidence":"siRNA formin screen with selective active-GTPase pulldowns and 3D invasion epistasis; isoform-selective RNAi for integrin surface expression; HUVEC and zebrafish endothelial assays","pmids":["20101212","20503409","26136364"],"confidence":"High","gaps":["structural basis of FMNL2/3 selectivity for RhoC not resolved","endothelial mechanisms from single lab"]},{"year":2011,"claim":"Resolved the spatial control of RhoC at invadopodia and defined its dedicated GEF/GAP pair, plus ROCK1/2 and FMNL3 partitioning of migratory polarity.","evidence":"RhoC FLARE biosensor live imaging with p190RhoGEF/p190RhoGAP localization and cofilin phosphorylation readouts; reciprocal RNAi with FMNL3/ROCK epistasis","pmids":["21474314","21576392"],"confidence":"High","gaps":["recruitment mechanism positioning p190RhoGEF vs p190RhoGAP unresolved","biosensor used in limited cell types"]},{"year":2011,"claim":"Established additional isoform-selective regulators and effectors—SmgGDS as a RhoA/RhoC-specific activator, PKN3 and IQGAP1 as preferential RhoC partners, and PKCε/p38γ/RhoGDIα as upstream controllers of RhoC activity and stability.","evidence":"In vitro exchange assays across a large GTPase panel with mutagenesis; Co-IP and in vitro kinase assays; RNAi/rescue epistasis and ubiquitination assays","pmids":["21242305","22217540","21537845","17018591","21862636","21757538"],"confidence":"Medium","gaps":["several interactions rest on single Co-IP studies","direct PKCε phosphorylation of RhoC inferred not proven","in vivo relevance of each axis variable"]},{"year":2012,"claim":"Demonstrated direct Akt1 phosphorylation of RhoC as essential for inflammatory breast cancer invasion, and confirmed IQGAP1 as a proliferative effector, linking specific kinase inputs to RhoC output.","evidence":"In vitro Akt1 kinase assay with phospho-specific detection and isoform-selective siRNA rescue; Co-IP and proliferation assays for IQGAP1","pmids":["22896661","23145020"],"confidence":"High","gaps":["phosphosite consequences on GTPase cycle not structurally defined","clinical correlation from single cohort"]},{"year":2013,"claim":"Quantified RhoC biochemical distinctiveness and effector binding (PRK/PKN affinities, ARHGAP21 GAP activity) and refined spatiotemporal models of RhoC vs RhoA during protrusion.","evidence":"In vitro binding/affinity assays, GAP activity assays, and FRET biosensor live imaging with computational analysis","pmids":["24128008","23200924","24224016","23704350"],"confidence":"Medium","gaps":["functional consequence of PRK affinity differences in cells untested","GAP studies from single lab"]},{"year":2017,"claim":"Placed RhoC within transcriptional/microenvironmental regulatory networks, with HIF-3α, Notch1, p53, and miRNAs (miR-10b, miR-493) controlling RhoC expression or RhoC-ROCK1 signaling.","evidence":"Transcriptional reporter/ChIP assays, miRNA 3'UTR luciferase and Co-IP, and pharmacological/genetic interventions with invasion readouts","pmids":["28928287","19953094","21079653","20843787","22057916"],"confidence":"Medium","gaps":["several transcriptional links inferred from reporter assays","context-dependence across tumor types not reconciled"]},{"year":2020,"claim":"Defined antagonistic and degradative control of RhoC—the RhoD-PAK6 axis suppressing RhoC-dependent contraction, RNF180 driving RhoC degradation, and ROCK-mediated endothelial transmigration—expanding the regulatory and effector network.","evidence":"Genetic epistasis in viral infection and normal cells, Co-IP plus ubiquitination proteomics, and RNAi cancer-endothelial interaction assays","pmids":["28486133","33082325","25677806"],"confidence":"High","gaps":["RNF180 link rests on single-lab Co-IP/proteomics","physiological setting for RhoD-PAK6 antagonism beyond viral context limited"]},{"year":2023,"claim":"Connected RhoC to metabolism, showing BCAT1 and branched-chain α-keto acids directly bind and activate RhoC to promote motility, defining a metabolite-driven activation mode.","evidence":"Co-IP of BCAT1-RhoC, in vitro BCKA-RhoC binding, activity assays, BCAT1E61A rescue, and in vivo peritoneal metastasis model","pmids":["37337119"],"confidence":"High","gaps":["binding site of BCKA on RhoC not structurally mapped","single-lab in vivo validation"]},{"year":null,"claim":"How the many isoform-selective regulators and effectors are integrated spatiotemporally in vivo, and the structural basis distinguishing RhoC from RhoA at the effector/regulator interface, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["no high-resolution structure of RhoC with its selective GEFs/GAPs/effectors","lack of in vivo causal ordering of the upstream kinase/metabolite/ubiquitin inputs","redundancy and compensation with RhoA not fully separated genetically"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003924","term_label":"GTPase activity","supporting_discovery_ids":[3,19,28,29]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[13,16,35]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[5,29]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[0,15]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[29]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[12,15,22]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,9]},{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[7]}],"complexes":[],"partners":["FMNL2","FMNL3","IQGAP1","ROCK1","ROCK2","PKN3","SMGGDS","BCAT1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P08134","full_name":"Rho-related GTP-binding protein RhoC","aliases":["Rho cDNA clone 9","h9"],"length_aa":193,"mass_kda":22.0,"function":"Regulates a signal transduction pathway linking plasma membrane receptors to the assembly of focal adhesions and actin stress fibers. Serves as a microtubule-dependent signal that is required for the myosin contractile ring formation during cell cycle cytokinesis. Regulates apical junction formation in bronchial epithelial cells","subcellular_location":"Cell membrane; Cleavage furrow","url":"https://www.uniprot.org/uniprotkb/P08134/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RHOC","classification":"Not Classified","n_dependent_lines":76,"n_total_lines":1208,"dependency_fraction":0.06291390728476821},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000155366","cell_line_id":"CID000587","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"nucleoplasm","grade":2}],"interactors":[{"gene":"ARHGDIA","stoichiometry":10.0},{"gene":"RHOA","stoichiometry":10.0},{"gene":"ARHGAP1","stoichiometry":0.2},{"gene":"RAP1GDS1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID000587","total_profiled":1310},"omim":[{"mim_id":"617043","title":"RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 17; ARHGEF17","url":"https://www.omim.org/entry/617043"},{"mim_id":"613394","title":"MICRO RNA 138-1; MIR138-1","url":"https://www.omim.org/entry/613394"},{"mim_id":"612115","title":"RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 3; ARHGEF3","url":"https://www.omim.org/entry/612115"},{"mim_id":"611576","title":"MICRO RNA 10B; MIR10B","url":"https://www.omim.org/entry/611576"},{"mim_id":"611410","title":"RHO FAMILY-INTERACTING CELL POLARIZATION REGULATOR 2; RIPOR2","url":"https://www.omim.org/entry/611410"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/RHOC"},"hgnc":{"alias_symbol":[],"prev_symbol":["ARH9","ARHC"]},"alphafold":{"accession":"P08134","domains":[{"cath_id":"3.40.50.300","chopping":"3-179","consensus_level":"high","plddt":96.9853,"start":3,"end":179}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P08134","model_url":"https://alphafold.ebi.ac.uk/files/AF-P08134-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P08134-F1-predicted_aligned_error_v6.png","plddt_mean":93.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RHOC","jax_strain_url":"https://www.jax.org/strain/search?query=RHOC"},"sequence":{"accession":"P08134","fasta_url":"https://rest.uniprot.org/uniprotkb/P08134.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P08134/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P08134"}},"corpus_meta":[{"pmid":"10952316","id":"PMC_10952316","title":"Genomic analysis of metastasis reveals an essential role for RhoC.","date":"2000","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/10952316","citation_count":1225,"is_preprint":false},{"pmid":"2501082","id":"PMC_2501082","title":"The mammalian G protein rhoC is ADP-ribosylated by Clostridium botulinum exoenzyme C3 and affects actin microfilaments in Vero cells.","date":"1989","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/2501082","citation_count":501,"is_preprint":false},{"pmid":"15501444","id":"PMC_15501444","title":"Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility.","date":"2004","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15501444","citation_count":389,"is_preprint":false},{"pmid":"9459160","id":"PMC_9459160","title":"Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas.","date":"1998","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9459160","citation_count":246,"is_preprint":false},{"pmid":"19536818","id":"PMC_19536818","title":"MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC.","date":"2009","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19536818","citation_count":244,"is_preprint":false},{"pmid":"16107613","id":"PMC_16107613","title":"RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis.","date":"2005","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/16107613","citation_count":243,"is_preprint":false},{"pmid":"21576392","id":"PMC_21576392","title":"RhoA and RhoC have distinct roles in migration and invasion by acting through different targets.","date":"2011","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21576392","citation_count":224,"is_preprint":false},{"pmid":"15668138","id":"PMC_15668138","title":"Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo.","date":"2005","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/15668138","citation_count":210,"is_preprint":false},{"pmid":"12808121","id":"PMC_12808121","title":"Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma.","date":"2003","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12808121","citation_count":192,"is_preprint":false},{"pmid":"20843787","id":"PMC_20843787","title":"Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20843787","citation_count":185,"is_preprint":false},{"pmid":"11839578","id":"PMC_11839578","title":"Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability.","date":"2002","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11839578","citation_count":171,"is_preprint":false},{"pmid":"24376640","id":"PMC_24376640","title":"MicroRNA-10b promotes nucleus pulposus cell proliferation through RhoC-Akt pathway by targeting HOXD10 in intervetebral disc degeneration.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24376640","citation_count":166,"is_preprint":false},{"pmid":"21474314","id":"PMC_21474314","title":"A novel spatiotemporal RhoC activation pathway locally regulates cofilin activity at invadopodia.","date":"2011","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/21474314","citation_count":148,"is_preprint":false},{"pmid":"23488932","id":"PMC_23488932","title":"RhoA, RhoB and RhoC have different roles in cancer cell migration.","date":"2013","source":"Journal of microscopy","url":"https://pubmed.ncbi.nlm.nih.gov/23488932","citation_count":139,"is_preprint":false},{"pmid":"14578459","id":"PMC_14578459","title":"Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells.","date":"2003","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/14578459","citation_count":125,"is_preprint":false},{"pmid":"11191108","id":"PMC_11191108","title":"RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells.","date":"2000","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/11191108","citation_count":124,"is_preprint":false},{"pmid":"15574779","id":"PMC_15574779","title":"Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15574779","citation_count":124,"is_preprint":false},{"pmid":"22293682","id":"PMC_22293682","title":"miR-10b promotes cell invasion through RhoC-AKT signaling pathway by targeting HOXD10 in gastric cancer.","date":"2012","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22293682","citation_count":121,"is_preprint":false},{"pmid":"20101212","id":"PMC_20101212","title":"Formin-like 2 drives amoeboid invasive cell motility downstream of RhoC.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20101212","citation_count":120,"is_preprint":false},{"pmid":"12221096","id":"PMC_12221096","title":"XPLN, a guanine nucleotide exchange factor for RhoA and RhoB, but not RhoC.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12221096","citation_count":119,"is_preprint":false},{"pmid":"18794150","id":"PMC_18794150","title":"RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancer.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18794150","citation_count":99,"is_preprint":false},{"pmid":"16187229","id":"PMC_16187229","title":"RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.","date":"2005","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/16187229","citation_count":91,"is_preprint":false},{"pmid":"22057916","id":"PMC_22057916","title":"Tumor suppressor microRNA-493 decreases cell motility and migration ability in human bladder cancer cells by downregulating RhoC and FZD4.","date":"2011","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/22057916","citation_count":89,"is_preprint":false},{"pmid":"31443665","id":"PMC_31443665","title":"LncRNA AFAP1-AS1 promotes tumorigenesis and epithelial-mesenchymal transition of osteosarcoma through RhoC/ROCK1/p38MAPK/Twist1 signaling pathway.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31443665","citation_count":85,"is_preprint":false},{"pmid":"12090470","id":"PMC_12090470","title":"Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer.","date":"2002","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/12090470","citation_count":85,"is_preprint":false},{"pmid":"14871999","id":"PMC_14871999","title":"A definitive role of RhoC in metastasis of orthotopic lung cancer in mice.","date":"2004","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/14871999","citation_count":85,"is_preprint":false},{"pmid":"15969750","id":"PMC_15969750","title":"Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and caveolin-1.","date":"2005","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15969750","citation_count":80,"is_preprint":false},{"pmid":"25659578","id":"PMC_25659578","title":"miR-509 suppresses brain metastasis of breast cancer cells by modulating RhoC and TNF-α.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25659578","citation_count":78,"is_preprint":false},{"pmid":"15736231","id":"PMC_15736231","title":"RhoA, RhoB, RhoC, Rac1, Cdc42, and Tc10 mRNA levels in spinal cord, sensory ganglia, and corticospinal tract neurons and long-lasting specific changes following spinal cord injury.","date":"2005","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15736231","citation_count":75,"is_preprint":false},{"pmid":"14696649","id":"PMC_14696649","title":"WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer.","date":"2004","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/14696649","citation_count":72,"is_preprint":false},{"pmid":"12479217","id":"PMC_12479217","title":"Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor.","date":"2002","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/12479217","citation_count":71,"is_preprint":false},{"pmid":"37337119","id":"PMC_37337119","title":"Enhanced BCAT1 activity and BCAA metabolism promotes RhoC activity in cancer progression.","date":"2023","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37337119","citation_count":70,"is_preprint":false},{"pmid":"21079653","id":"PMC_21079653","title":"p53-mediated transcriptional regulation and activation of the actin cytoskeleton regulatory RhoC to LIMK2 signaling pathway promotes cell survival.","date":"2010","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/21079653","citation_count":68,"is_preprint":false},{"pmid":"25236186","id":"PMC_25236186","title":"miR-10b is overexpressed in hepatocellular carcinoma and promotes cell proliferation, migration and invasion through RhoC, uPAR and MMPs.","date":"2014","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25236186","citation_count":66,"is_preprint":false},{"pmid":"17018591","id":"PMC_17018591","title":"Targeted disruption of protein kinase C epsilon reduces cell invasion and motility through inactivation of RhoA and RhoC GTPases in head and neck squamous cell carcinoma.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17018591","citation_count":65,"is_preprint":false},{"pmid":"22911725","id":"PMC_22911725","title":"RhoC impacts the metastatic potential and abundance of breast cancer stem cells.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22911725","citation_count":61,"is_preprint":false},{"pmid":"16750623","id":"PMC_16750623","title":"RhoA and RhoC proteins promote both cell proliferation and cell invasion of human oesophageal squamous cell carcinoma cell lines in vitro and in vivo.","date":"2006","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/16750623","citation_count":61,"is_preprint":false},{"pmid":"14999149","id":"PMC_14999149","title":"RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells.","date":"2004","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/14999149","citation_count":60,"is_preprint":false},{"pmid":"20503409","id":"PMC_20503409","title":"Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancers.","date":"2010","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20503409","citation_count":60,"is_preprint":false},{"pmid":"28928287","id":"PMC_28928287","title":"HIF-3α Promotes Metastatic Phenotypes in Pancreatic Cancer by Transcriptional Regulation of the RhoC-ROCK1 Signaling Pathway.","date":"2017","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/28928287","citation_count":59,"is_preprint":false},{"pmid":"16470169","id":"PMC_16470169","title":"RhoC promotes human melanoma invasion in a PI3K/Akt-dependent pathway.","date":"2006","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/16470169","citation_count":57,"is_preprint":false},{"pmid":"16314838","id":"PMC_16314838","title":"RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16314838","citation_count":57,"is_preprint":false},{"pmid":"14614010","id":"PMC_14614010","title":"Higher expression of RhoC is related to invasiveness in non-small cell lung carcinoma.","date":"2003","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/14614010","citation_count":57,"is_preprint":false},{"pmid":"25649143","id":"PMC_25649143","title":"RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.","date":"2015","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25649143","citation_count":57,"is_preprint":false},{"pmid":"23200924","id":"PMC_23200924","title":"ARHGAP21 is a RhoGAP for RhoA and RhoC with a role in proliferation and migration of prostate adenocarcinoma cells.","date":"2012","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23200924","citation_count":57,"is_preprint":false},{"pmid":"23704350","id":"PMC_23704350","title":"Spatial regulation of RhoC activity defines protrusion formation in migrating cells.","date":"2013","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/23704350","citation_count":56,"is_preprint":false},{"pmid":"36306821","id":"PMC_36306821","title":"A current overview of RhoA, RhoB, and RhoC functions in vascular biology and pathology.","date":"2022","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36306821","citation_count":55,"is_preprint":false},{"pmid":"12970882","id":"PMC_12970882","title":"Expression and significance of RhoC gene in hepatocellular carcinoma.","date":"2003","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/12970882","citation_count":55,"is_preprint":false},{"pmid":"21242305","id":"PMC_21242305","title":"SmgGDS is a guanine nucleotide exchange factor that specifically activates RhoA and RhoC.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21242305","citation_count":55,"is_preprint":false},{"pmid":"18980974","id":"PMC_18980974","title":"Inhibition of invasion and metastasis of hepatocellular carcinoma cells via targeting RhoC in vitro and in vivo.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18980974","citation_count":54,"is_preprint":false},{"pmid":"16899593","id":"PMC_16899593","title":"RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck.","date":"2006","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/16899593","citation_count":54,"is_preprint":false},{"pmid":"19953094","id":"PMC_19953094","title":"Notch1 regulates the functional contribution of RhoC to cervical carcinoma progression.","date":"2009","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19953094","citation_count":53,"is_preprint":false},{"pmid":"21862636","id":"PMC_21862636","title":"p38γ promotes breast cancer cell motility and metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a novel leading edge behavior.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21862636","citation_count":52,"is_preprint":false},{"pmid":"22896661","id":"PMC_22896661","title":"Regulation of inflammatory breast cancer cell invasion through Akt1/PKBα phosphorylation of RhoC GTPase.","date":"2012","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/22896661","citation_count":52,"is_preprint":false},{"pmid":"27991524","id":"PMC_27991524","title":"Macrophages Enhance Migration in Inflammatory Breast Cancer Cells via RhoC GTPase Signaling.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27991524","citation_count":48,"is_preprint":false},{"pmid":"23648017","id":"PMC_23648017","title":"Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis.","date":"2013","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23648017","citation_count":47,"is_preprint":false},{"pmid":"25213860","id":"PMC_25213860","title":"Mouse macrophages completely lacking Rho subfamily GTPases (RhoA, RhoB, and RhoC) have severe lamellipodial retraction defects, but robust chemotactic navigation and altered motility.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25213860","citation_count":47,"is_preprint":false},{"pmid":"14555841","id":"PMC_14555841","title":"Expression of RHOC is associated with metastasis of gastric carcinomas.","date":"2004","source":"Pathobiology : journal of immunopathology, molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14555841","citation_count":47,"is_preprint":false},{"pmid":"17549441","id":"PMC_17549441","title":"RhoC is essential for the metastasis of gastric cancer.","date":"2007","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/17549441","citation_count":46,"is_preprint":false},{"pmid":"17659701","id":"PMC_17659701","title":"RhoA and RhoC -siRNA inhibit the proliferation and invasiveness activity of human gastric carcinoma by Rho/PI3K/Akt pathway.","date":"2007","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/17659701","citation_count":46,"is_preprint":false},{"pmid":"31340863","id":"PMC_31340863","title":"RhoC: a fascinating journey from a cytoskeletal organizer to a Cancer stem cell therapeutic target.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31340863","citation_count":44,"is_preprint":false},{"pmid":"24565984","id":"PMC_24565984","title":"Down regulation of RhoC by microRNA-138 results in de-activation of FAK, Src and Erk1/2 signaling pathway in head and neck squamous cell carcinoma.","date":"2014","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24565984","citation_count":44,"is_preprint":false},{"pmid":"28949796","id":"PMC_28949796","title":"RhoA, RhoB and RhoC differentially regulate endothelial barrier function.","date":"2017","source":"Small GTPases","url":"https://pubmed.ncbi.nlm.nih.gov/28949796","citation_count":43,"is_preprint":false},{"pmid":"24224016","id":"PMC_24224016","title":"A RhoC biosensor reveals differences in the activation kinetics of RhoA and RhoC in migrating cells.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24224016","citation_count":43,"is_preprint":false},{"pmid":"24533098","id":"PMC_24533098","title":"RhoC regulates cancer stem cells in head and neck squamous cell carcinoma by overexpressing IL-6 and phosphorylation of STAT3.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24533098","citation_count":43,"is_preprint":false},{"pmid":"22217540","id":"PMC_22217540","title":"The interaction of PKN3 with RhoC promotes malignant growth.","date":"2011","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22217540","citation_count":42,"is_preprint":false},{"pmid":"30683109","id":"PMC_30683109","title":"Epigenetic inactivation of HOXD10 is associated with human colon cancer via inhibiting the RHOC/AKT/MAPK signaling pathway.","date":"2019","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/30683109","citation_count":40,"is_preprint":false},{"pmid":"22895562","id":"PMC_22895562","title":"Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder.","date":"2012","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/22895562","citation_count":39,"is_preprint":false},{"pmid":"29507753","id":"PMC_29507753","title":"Long non-coding RNA MT1DP shunts the cellular defense to cytotoxicity through crosstalk with MT1H and RhoC in cadmium stress.","date":"2018","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/29507753","citation_count":39,"is_preprint":false},{"pmid":"26136364","id":"PMC_26136364","title":"RhoC maintains vascular homeostasis by regulating VEGF-induced signaling in endothelial cells.","date":"2015","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/26136364","citation_count":38,"is_preprint":false},{"pmid":"26673619","id":"PMC_26673619","title":"MicroRNA-372 inhibits endometrial carcinoma development by targeting the expression of the Ras homolog gene family member C (RhoC).","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26673619","citation_count":36,"is_preprint":false},{"pmid":"26741994","id":"PMC_26741994","title":"The Role of RhoA, RhoB and RhoC GTPases in Cell Morphology, Proliferation and Migration in Human Cytomegalovirus (HCMV) Infected Glioblastoma Cells.","date":"2016","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26741994","citation_count":35,"is_preprint":false},{"pmid":"27837031","id":"PMC_27837031","title":"Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma.","date":"2016","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/27837031","citation_count":35,"is_preprint":false},{"pmid":"19861405","id":"PMC_19861405","title":"RhoC expression and head and neck cancer metastasis.","date":"2009","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/19861405","citation_count":32,"is_preprint":false},{"pmid":"25559359","id":"PMC_25559359","title":"Caveolin-1 mediates inflammatory breast cancer cell invasion via the Akt1 pathway and RhoC GTPase.","date":"2015","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25559359","citation_count":32,"is_preprint":false},{"pmid":"24986540","id":"PMC_24986540","title":"The role of RhoC in epithelial-to-mesenchymal transition of ovarian carcinoma cells.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24986540","citation_count":32,"is_preprint":false},{"pmid":"24128008","id":"PMC_24128008","title":"Differential binding of RhoA, RhoB, and RhoC to protein kinase C-related kinase (PRK) isoforms PRK1, PRK2, and PRK3: PRKs have the highest affinity for RhoB.","date":"2013","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24128008","citation_count":32,"is_preprint":false},{"pmid":"31488179","id":"PMC_31488179","title":"RhoC regulates radioresistance via crosstalk of ROCK2 with the DNA repair machinery in cervical cancer.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31488179","citation_count":31,"is_preprint":false},{"pmid":"23145020","id":"PMC_23145020","title":"RhoC regulates the proliferation of gastric cancer cells through interaction with IQGAP1.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23145020","citation_count":31,"is_preprint":false},{"pmid":"18614849","id":"PMC_18614849","title":"Possible role of the RhoC/ROCK pathway in progression of clear cell renal cell carcinoma.","date":"2008","source":"Biomedical research (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/18614849","citation_count":30,"is_preprint":false},{"pmid":"25933027","id":"PMC_25933027","title":"Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25933027","citation_count":30,"is_preprint":false},{"pmid":"19222696","id":"PMC_19222696","title":"The role of RhoC in growth and metastatic capacity of melanoma.","date":"2009","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19222696","citation_count":30,"is_preprint":false},{"pmid":"34627249","id":"PMC_34627249","title":"Role of RhoC in cancer cell migration.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/34627249","citation_count":29,"is_preprint":false},{"pmid":"33082325","id":"PMC_33082325","title":"RNF180 mediates STAT3 activity by regulating the expression of RhoC via the proteasomal pathway in gastric cancer cells.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33082325","citation_count":28,"is_preprint":false},{"pmid":"23036489","id":"PMC_23036489","title":"Knockdown of Hop downregulates RhoC expression, and decreases pseudopodia formation and migration in cancer cell lines.","date":"2012","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/23036489","citation_count":28,"is_preprint":false},{"pmid":"28486133","id":"PMC_28486133","title":"RhoD Inhibits RhoC-ROCK-Dependent Cell Contraction via PAK6.","date":"2017","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/28486133","citation_count":27,"is_preprint":false},{"pmid":"24642482","id":"PMC_24642482","title":"Spatial regulation of tumor cell protrusions by RhoC.","date":"2014","source":"Cell adhesion & migration","url":"https://pubmed.ncbi.nlm.nih.gov/24642482","citation_count":27,"is_preprint":false},{"pmid":"29500478","id":"PMC_29500478","title":"Transcriptional and post-transcriptional regulation of the genes encoding the small GTPases RhoA, RhoB, and RhoC: implications for the pathogenesis of human diseases.","date":"2018","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/29500478","citation_count":27,"is_preprint":false},{"pmid":"33828938","id":"PMC_33828938","title":"MMP-9 Knockdown Inhibits Oral Squamous Cell Carcinoma Lymph Node Metastasis in the Nude Mouse Tongue-Xenografted Model through the RhoC/Src Pathway.","date":"2021","source":"Analytical cellular pathology (Amsterdam)","url":"https://pubmed.ncbi.nlm.nih.gov/33828938","citation_count":27,"is_preprint":false},{"pmid":"32314833","id":"PMC_32314833","title":"Cytotoxic necrotizing factor 1 promotes bladder cancer angiogenesis through activating RhoC.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32314833","citation_count":27,"is_preprint":false},{"pmid":"20824700","id":"PMC_20824700","title":"Farnesyl transferase inhibitor treatment of breast cancer cells leads to altered RhoA and RhoC GTPase activity and induces a dormant phenotype.","date":"2010","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20824700","citation_count":27,"is_preprint":false},{"pmid":"30228782","id":"PMC_30228782","title":"Formin-like 3 regulates RhoC/FAK pathway and actin assembly to promote cell invasion in colorectal carcinoma.","date":"2018","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/30228782","citation_count":26,"is_preprint":false},{"pmid":"21757538","id":"PMC_21757538","title":"RhoGDIα-dependent balance between RhoA and RhoC is a key regulator of cancer cell tumorigenesis.","date":"2011","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/21757538","citation_count":26,"is_preprint":false},{"pmid":"21732343","id":"PMC_21732343","title":"ETS-1/RhoC signaling regulates the transcription factor c-Jun in melanoma.","date":"2011","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21732343","citation_count":26,"is_preprint":false},{"pmid":"19499974","id":"PMC_19499974","title":"Expression of RhoA and RhoC in colorectal carcinoma and its relations with clinicopathological parameters.","date":"2009","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19499974","citation_count":25,"is_preprint":false},{"pmid":"30779947","id":"PMC_30779947","title":"RhoC/ROCK2 promotes vasculogenic mimicry formation primarily through ERK/MMPs in hepatocellular carcinoma.","date":"2019","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/30779947","citation_count":25,"is_preprint":false},{"pmid":"19642867","id":"PMC_19642867","title":"Specific induction of migration and invasion of pancreatic carcinoma cells by RhoC, which differs from RhoA in its localisation and activity.","date":"2009","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19642867","citation_count":25,"is_preprint":false},{"pmid":"25677806","id":"PMC_25677806","title":"RhoC and ROCKs regulate cancer cell interactions with endothelial cells.","date":"2015","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25677806","citation_count":24,"is_preprint":false},{"pmid":"27108649","id":"PMC_27108649","title":"Knockdown of RHOC by shRNA suppresses invasion and migration of cholangiocellular carcinoma cells via inhibition of MMP2, MMP3, MMP9 and epithelial-mesenchymal transition.","date":"2016","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/27108649","citation_count":24,"is_preprint":false},{"pmid":"21537845","id":"PMC_21537845","title":"RhoC protein stimulates migration of gastric cancer cells through interaction with scaffold protein IQGAP1.","date":"2011","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/21537845","citation_count":23,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50814,"output_tokens":10362,"usd":0.153936,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21012,"output_tokens":5122,"usd":0.116555,"stage2_stop_reason":"end_turn"},"total_usd":0.270491,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"RhoC protein is ADP-ribosylated by Clostridium botulinum exoenzyme C3, and C3 treatment of Vero cells causes disappearance of actin microfilaments and actinomorphic shape changes, establishing that a rho protein (RhoC) regulates actin microfilament assembly.\",\n      \"method\": \"Bacterial expression of human rhoC gene product, in vitro ADP-ribosylation assay, cell treatment with C3 exoenzyme and morphological analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct biochemical assay (ADP-ribosylation) combined with cell biological readout (microfilament disassembly), foundational paper replicated in many subsequent studies\",\n      \"pmids\": [\"2501082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Overexpression of RhoC in melanoma cells enhances metastasis and invasion, while dominant-negative Rho inhibits metastasis, establishing RhoC as a functional driver of tumor cell invasion in vivo.\",\n      \"method\": \"In vivo selection of metastatic melanoma cells, DNA microarray gene expression analysis, overexpression and dominant-negative constructs, in vivo metastasis assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal gain- and loss-of-function in vivo, replicated across subsequent studies in multiple cancer types\",\n      \"pmids\": [\"10952316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"RhoC GTPase overexpression in human mammary epithelial cells increases production of angiogenic factors (VEGF, bFGF, IL-6, IL-8); inhibition of RhoC with C3 exotransferase decreases angiogenic factor production, directly linking RhoC activity to angiogenic signaling.\",\n      \"method\": \"Stable transfection of RhoC in HME cells, ELISA measurement of conditioned media, C3 exotransferase inhibition\",\n      \"journal\": \"Neoplasia (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — orthogonal gain-of-function and pharmacological inhibition, quantitative ELISA readout, single lab\",\n      \"pmids\": [\"11191108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"XPLN, a guanine nucleotide exchange factor, stimulates GDP/GTP exchange on RhoA and RhoB but NOT RhoC in vitro; the inability to activate RhoC is determined by isoleucine 43 in RhoC (a position occupied by valine in RhoA and RhoB), establishing a structural basis for GEF selectivity among Rho isoforms.\",\n      \"method\": \"In vitro nucleotide exchange assays, preferential binding assays, site-specific mutagenesis (Ile43 in RhoC), cellular stress fiber/focal adhesion assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro exchange assay with mutagenesis identifying the specific residue, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"12221096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Activation of the MAPK pathway downstream of RhoC GTPase is responsible for motility, invasion, and production of angiogenic factors in inflammatory breast cancer cells, while PI3K pathway activation drives anchorage-independent growth.\",\n      \"method\": \"Pharmacological inhibitors of MAPK and PI3K pathways in HME-RhoC transfectants and SUM149 IBC cells; motility, invasion, and angiogenesis assays\",\n      \"journal\": \"Clinical & experimental metastasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection with defined functional readouts, single lab\",\n      \"pmids\": [\"12090470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Atorvastatin prevents geranylgeranylation (isoprenylation) of RhoC, inhibiting its subcellular localization and activity, and blocks melanoma cell invasion in vitro and in vivo metastasis of RhoC-overexpressing cells, establishing that RhoC biological activity depends on posttranslational geranylgeranylation.\",\n      \"method\": \"HMG-CoA reductase inhibitor treatment, subcellular fractionation and Rho activity assays, in vitro invasion assays, in vivo melanoma metastasis model\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition with mechanistic localization assay and in vivo validation, single lab\",\n      \"pmids\": [\"14578459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"RhoC stimulates invasion but not proliferation in invasive breast carcinoma (SUM-159) cells; RhoA impedes invasion; a compensatory relationship exists between RhoA and RhoC expression/activation levels, and RhoC depletion inversely affects Rac1 activation.\",\n      \"method\": \"Stable retroviral RNAi knockdown of RhoA or RhoC, invasion assays, Rho and Rac1 activity measurements\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — selective RNAi knockdown with defined functional readouts, single lab\",\n      \"pmids\": [\"15574779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"In orthotopic lung cancer mouse model, RhoC overexpression enhances metastasis and increases MMP-2 activity, while dominant-negative Rho suppresses both, without affecting primary tumor growth; establishing RhoC as a promoter of metastasis through MMP upregulation.\",\n      \"method\": \"Retroviral transduction of RhoC or dominant-negative Rho into murine lung cancer cells, orthotopic intrapulmonary inoculation, RT-PCR and gelatin zymography for MMPs\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo model with mechanistic MMP analysis, single lab\",\n      \"pmids\": [\"14871999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Loss of WISP3 in HME cells increases RhoC mRNA and protein levels, while restoration of WISP3 in IBC cells decreases RhoC protein, indicating that WISP3 modulates RhoC expression and the two genes cooperate in the IBC phenotype.\",\n      \"method\": \"Antisense inhibition of WISP3, RT-PCR and Western blot for RhoC, VEGF ELISA, soft agar growth assays\",\n      \"journal\": \"Breast cancer research : BCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain- and loss-of-function, single lab\",\n      \"pmids\": [\"14696649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"RhoC-deficient mice (RhoC knockout) are viable and fertile; loss of RhoC does not affect tumor development but decreases tumor cell motility and metastatic cell survival, leading to drastic inhibition of metastasis, establishing RhoC as specifically required for metastasis but dispensable for embryogenesis and tumor initiation.\",\n      \"method\": \"RhoC knockout mouse generation, tumor induction models, cell motility and survival assays, metastasis quantification\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic knockout with multiple phenotypic readouts, defines the in vivo requirement of RhoC for metastasis\",\n      \"pmids\": [\"16107613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RhoC is required for invasion but not random motility in PC-3 prostate cancer cells; inhibition of RhoC with C3 exotransferase or dominant-negative RhoC promotes IGF-I-stimulated random motility but decreases invasion and experimental metastasis, and causes alterations in focal adhesion protein distribution.\",\n      \"method\": \"C3 exotransferase pharmacological inhibition and dominant-negative RhoC overexpression, chemotaxis chamber assays, in vivo experimental metastasis, immunofluorescence of focal adhesion proteins\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two inhibitory approaches with defined mechanistic readouts, single lab\",\n      \"pmids\": [\"16314838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PKCε knockdown in HNSCC cells reduces active and serine-phosphorylated RhoA and RhoC; constitutively active RhoC rescues invasion and partially rescues motility in PKCε-deficient cells, establishing RhoC as a downstream effector of PKCε, possibly through direct post-translational phosphorylation.\",\n      \"method\": \"siRNA knockdown of PKCε, constitutively active RhoC rescue experiments, invasion and motility assays, Western blot for phospho-RhoC/RhoA\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi + rescue epistasis, single lab\",\n      \"pmids\": [\"17018591\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RhoC promotes prostate cancer metastasis via sequential activation of Pyk2, FAK, MAPK, and Akt, followed by upregulation of MMP2 and MMP9; inhibition of Pyk2 blocks RhoC-dependent activation of FAK, MAPK, and Akt and suppresses MMP activity.\",\n      \"method\": \"RhoC overexpression in prostate cancer cells, antibody array for signaling molecules, Pyk2 kinase inhibitor treatment, in vitro invasion/motility assays, in vivo metastasis model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — signaling pathway dissection with pharmacological inhibitors and defined readouts, single lab\",\n      \"pmids\": [\"18794150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Formin-like 2 (FMNL2) is a specific effector of RhoC but not RhoA or RhoB; FMNL2 shows selective interaction with active RhoC, and RhoC regulates FMNL2 autoinhibition; suppression of FMNL2 inhibits RhoC-dependent but not RhoA-dependent rounded invasive cell migration.\",\n      \"method\": \"siRNA-based screen of all 15 human formins in 3D cell motility, selective pulldown with active GTPase forms, knockdown rescue experiments in cancer cell lines\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic siRNA screen plus selective protein interaction assays, epistasis in 3D invasion, multiple cell lines\",\n      \"pmids\": [\"20101212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"HA-induced CD44 interaction with c-Src kinase activates Twist, which drives miR-10b transcription; miR-10b suppresses HOXD10, leading to RhoA/RhoC upregulation and ROCK activation, resulting in breast tumor cell invasion. This pathway is abrogated by c-Src inhibition, Twist siRNA, or anti-miR-10b inhibitor.\",\n      \"method\": \"ChIP assays for Twist at miR-10b promoter, siRNA and inhibitor experiments, Western blot for RhoC/RhoA/ROK, invasion assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and multiple orthogonal interventions in a single cell line system, single lab\",\n      \"pmids\": [\"20843787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"RhoC activity is spatially confined to areas surrounding invadopodia, regulated by p190RhoGEF (which localizes around invadopodia to activate RhoC) and p190RhoGAP (which localizes inside invadopodia to deactivate RhoC); RhoC activation surrounding invadopodia enhances cofilin phosphorylation outside the structure, restricting cofilin-mediated actin barbed end generation to within the invadopodium core.\",\n      \"method\": \"Live-cell imaging with fluorescent RhoC FLARE biosensor, immunofluorescence localization of p190RhoGEF and p190RhoGAP, cofilin phosphorylation assays\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — live biosensor imaging combined with spatial localization and biochemical readouts, establishes mechanism at subcellular resolution\",\n      \"pmids\": [\"21474314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"RhoC depletion increases cell spreading and induces Rac1 activation around the cell periphery in broad lamellipodia, inhibiting directed migration and invasion; these effects are mediated by formin FMNL3, identified as a new effector of RhoC but not RhoA; RhoA acts through ROCK1/ROCK2 to regulate migratory polarity.\",\n      \"method\": \"RNAi knockdown of RhoA and RhoC, 2D and 3D migration/invasion assays, Rac1 activity measurements, FMNL3 knockdown rescue epistasis\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal RNAi with multiple rescue and epistasis experiments, two orthogonal 2D/3D assays, identifies FMNL3 as RhoC-specific effector\",\n      \"pmids\": [\"21576392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"p38γ MAPK regulates RhoC expression by modulating RhoC ubiquitination; p38γ knockdown reduces RhoC protein levels and inhibits breast cancer cell motility and metastasis.\",\n      \"method\": \"p38γ knockdown, Western blot for RhoC, ubiquitination assay, motility assays, computational cell mechanics model, clinical specimen correlation\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic ubiquitination assay plus KD functional readout, single lab\",\n      \"pmids\": [\"21862636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PKN3 physically interacts preferentially with RhoC over other Rho GTPases; PKN3 catalytic activity is increased in the presence of Rho GTPases; the PKN3-RhoC complex is co-expressed in late-stage malignancies and contributes to tumor invasion and metastasis.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase activity assay with Rho GTPases, orthotopic mouse tumor models with PKN3 knockdown\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus in vitro kinase assay, single lab\",\n      \"pmids\": [\"22217540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SmgGDS exclusively activates RhoA and RhoC (not other tested GTPases) in vitro; this specificity is catalytic and requires the polybasic region of RhoA for activation; SmgGDS uses a distinct exchange mechanism from canonical GEFs. This specificity is retained in cells.\",\n      \"method\": \"In vitro nucleotide exchange assays on a large panel of purified GTPases, mutagenesis of SmgGDS and RhoA, preferential nucleotide-depleted state binding assay, cellular GEF activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with large GTPase panel, mutagenesis, mechanistic characterization, and cellular validation\",\n      \"pmids\": [\"21242305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"RhoC and IQGAP1 bind to each other (co-immunoprecipitation); RhoC stimulates migration of gastric cancer cells through IQGAP1 as a downstream effector; knockdown of IQGAP1 blocks RhoC-induced migration stimulation.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown of RhoC and IQGAP1, constitutively active RhoC overexpression, transwell migration assay\",\n      \"journal\": \"Molecular medicine reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP plus epistatic knockdown rescue, single lab\",\n      \"pmids\": [\"21537845\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"RhoGDIα-mediated balance between RhoA and RhoC controls invasive phenotype; RhoC silencing increases expression of tumor suppressor NAG-1 and reduces migration and anchorage-independent growth; this occurs indirectly through upregulation of RhoA via competition for RhoGDIα.\",\n      \"method\": \"siRNA knockdown of RhoC, RhoA, and RhoGDIα, RhoA mutant unable to bind RhoGDIα, gene expression profiling, migration and soft agar assays, in vivo tumor growth\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple siRNA knockdowns with rescue epistasis, defined molecular mechanism through RhoGDIα competition, single lab\",\n      \"pmids\": [\"21757538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Akt1 directly phosphorylates RhoC GTPase, and this phosphorylation is absolutely essential for IBC cell invasion; Akt3 (not Akt1) regulates IBC cell survival; PI3K/Akt1/RhoC pathway is specifically upregulated in IBC patients.\",\n      \"method\": \"In vitro Akt1 kinase assay with RhoC substrate, phospho-specific detection, siRNA knockdown of Akt isoforms, invasion assays, clinical IBC specimen analysis\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay demonstrating direct phosphorylation plus functional rescue experiments, single lab with clinical correlation\",\n      \"pmids\": [\"22896661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"RhoC and IQGAP1 bind each other; RhoC stimulates gastric cancer cell proliferation through IQGAP1 by increasing cyclin E and cyclin D1 levels; IQGAP1 knockdown blocks RhoC-induced proliferation but not vice versa, defining IQGAP1 as a downstream effector of RhoC in proliferation.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence co-localization, siRNA knockdown, constitutively active RhoC overexpression, MTT and BrdU proliferation assays, Western blot for cyclins\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, co-localization, and epistatic knockdown with defined molecular readouts, single lab\",\n      \"pmids\": [\"23145020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A RhoC FLARE biosensor revealed that RhoC activity is higher than RhoA in regions distal from the cell edge during protrusion; RhoC activation precedes RhoA activation distally before edge protrusion; p190RhoGEF and p190RhoGAP regulate actin barbed end distribution and protrusion directionality through RhoC activity balance.\",\n      \"method\": \"FRET-based RhoC FLARE biosensor live imaging, comparison with RhoA biosensor, computational analysis of spatio-temporal GTPase activity during protrusion/retraction and macropinocytosis\",\n      \"journal\": \"PloS one / Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — validated biosensor with live imaging and computational analysis, comparison across two isoforms with two independent labs using similar approaches\",\n      \"pmids\": [\"24224016\", \"23704350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RhoC promotes vascular homeostasis in endothelial cells: it stimulates proliferation by stabilizing nuclear β-catenin (promoting cyclin D1 transcription); negatively regulates migration through MAPKs/MLC2 signaling; and decreases vascular permeability through downregulation of PLCγ-Ca2+-eNOS cascade. RhoC morpholino in zebrafish increases vascular permeability.\",\n      \"method\": \"HUVEC siRNA/overexpression experiments, Western blot for β-catenin/cyclin D1/MLC2/eNOS, permeability assays, zebrafish RhoC morpholino model\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple mechanistic readouts in endothelial cells plus in vivo zebrafish validation, single lab\",\n      \"pmids\": [\"26136364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RhoC promotes melanoma invasion through a PI3K/Akt pathway independent of ROCK signaling; RhoC overexpression increases phospho-Akt (Ser473); inhibition of PI3K or Akt (but not ROCK) decreases pAkt levels; both ROCK and PI3K/Akt pathways contribute independently to RhoC-driven invasion.\",\n      \"method\": \"Stable RhoC overexpression in melanoma cells, C3 transferase inhibition, PI3K/Akt/ROCK pharmacological inhibitors, Western blot for pAkt, invasion assays\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection of parallel pathways with mechanistic readouts, single lab\",\n      \"pmids\": [\"16470169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RhoC (but not RhoA) modulates surface expression and colocalization of α2 and β1 integrins in MDA-MB-231 cells on collagen I, establishing a specific role for RhoC in cell-matrix adhesion through integrin regulation.\",\n      \"method\": \"Selective siRNA knockdown of RHOC vs RHOA, flow cytometry and immunofluorescence for integrin surface expression, collagen I and Matrigel invasion/adhesion assays\",\n      \"journal\": \"Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-selective RNAi with specific integrin readout, single lab\",\n      \"pmids\": [\"20503409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ARHGAP21 functions as a RhoGAP with enzymatic activity toward both RhoA and RhoC; its depletion in PC3 prostate cancer cells decreases proliferation and increases migration.\",\n      \"method\": \"In vitro GAP activity assay for RhoA and RhoC, siRNA knockdown in LNCaP and PC3 cells, proliferation and migration assays\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro GAP assay defining substrate specificity, plus functional cellular KD, single lab\",\n      \"pmids\": [\"23200924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"RhoC has higher intrinsic GTP binding affinity, faster intrinsic and GEF-stimulated GDP/GTP exchange rates than RhoA; RhoC is predominantly localized in the membrane-containing fraction whereas RhoA is mainly cytoplasmic; these biochemical differences are not due to differential RhoGDI interaction and correlate with RhoC-specific enhancement of migration and invasion in pancreatic carcinoma cells.\",\n      \"method\": \"In vitro GTP/GDP binding and exchange assays, subcellular fractionation, RhoGDI interaction assays, serum-response factor reporter assays, migration and invasion assays\",\n      \"journal\": \"Biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical assays with subcellular fractionation and functional validation, rigorous mechanistic characterization, single lab\",\n      \"pmids\": [\"19642867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Differential binding affinities of PRK isoforms (PRK1, PRK2, PRK3) for RhoA, RhoB, and RhoC were measured; RhoA and RhoC bind PRK1 HR1a domain with similar affinities; PRK2 and PRK3 domains bind all Rho isoforms less well than PRK1; establishing quantitative interaction parameters for RhoC-PRK signaling.\",\n      \"method\": \"In vitro binding/affinity assays using purified HR1 domain constructs and purified Rho GTPases, thermal stability analysis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with quantitative binding measurements, single lab\",\n      \"pmids\": [\"24128008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"p53 directly transcriptionally activates RhoC and LIMK2 expression in response to genotoxic agents; LIMK2 activation downstream of RhoC has a pro-survival function following DNA damage; LIMK inhibition sensitizes cells to radio- or chemotherapy.\",\n      \"method\": \"ChIP (implied by 'direct p53 target genes'), siRNA knockdown of LIMK2, pharmacological LIMK inhibition, genotoxic agent treatment, cell survival assays\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — p53 target gene identification with functional downstream analysis, single lab\",\n      \"pmids\": [\"21079653\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Notch1 signaling regulates RhoC activity in cervical carcinoma; Notch1 inhibition with DAPT decreases RhoC activity; constitutively active RhoC rescues the phenotypic effects of Notch1 inactivation on invasion, migration, and anoikis resistance, placing RhoC as an effector of Notch1.\",\n      \"method\": \"Pharmacological Notch1 inhibition with DAPT, Rho activity assay (G-LISA), constitutively active RhoC rescue experiments, invasion/migration/anoikis assays\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition plus constitutively active rescue epistasis, single lab\",\n      \"pmids\": [\"19953094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"miR-493 decreases RhoC 3'UTR luciferase activity and protein expression in bladder cancer cells, and decreases RhoC-ROCK1 binding, thereby reducing cell motility and migration.\",\n      \"method\": \"miR-493 transfection, 3'UTR luciferase reporter assay, Western blot for RhoC, co-immunoprecipitation for RhoC-ROCK1 interaction, migration assays\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase 3'UTR assay plus Co-IP for RhoC-ROCK1, single lab\",\n      \"pmids\": [\"22057916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HIF-3α promotes pancreatic cancer invasion by transcriptionally activating the RhoC-ROCK1 signaling pathway under hypoxic and normoxic conditions; HIF-3α overexpression stimulates F-actin polymerization.\",\n      \"method\": \"HIF-3α knockdown and overexpression, ChIP/transcriptional reporter assays for RhoC promoter (implied), invasion/migration assays, F-actin staining, in vivo xenograft\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptional regulation assay with gain/loss of function and functional readouts, single lab\",\n      \"pmids\": [\"28928287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"RhoD recruits PAK6 to the plasma membrane to antagonize RhoC signaling and suppress RhoC-dependent cell contraction and blebbing; vaccinia virus F11 protein inhibits RhoD, thereby relieving PAK6 suppression of RhoC and enabling ROCK-mediated cell contraction specifically through RhoC (not RhoA).\",\n      \"method\": \"Vaccinia infection model, RhoC/RhoD/PAK6 knockdowns, localization studies, ROCK inhibition, genetic epistasis with constitutively active/dominant-negative constructs\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic epistasis experiments establishing the RhoD-PAK6-RhoC signaling axis, mechanistic dissection in viral infection context and normal cells\",\n      \"pmids\": [\"28486133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"RhoC depletion by RNAi reduces PC3 prostate cancer cell adhesion to endothelial cells, intercalation between endothelial cells, and transendothelial migration in vitro; ROCK1 and ROCK2 depletion similarly decreases cancer-endothelial interactions; RhoC depletion reduces early lung retention and experimental metastasis in vivo.\",\n      \"method\": \"RNAi depletion of RhoC, ROCK1, ROCK2; adhesion, intercalation, transendothelial migration assays; in vivo lung retention and metastasis experiments\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple RNAi knockdowns with in vitro and in vivo functional readouts, single lab\",\n      \"pmids\": [\"25677806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"RhoC promotes radioresistance in cervical cancer via ROCK2, which interacts with DNA repair pathway proteins (pH2Ax, MRE11, RAD50); ROCK2 inhibition reduces expression of pH2Ax and MRN complex proteins, and abolishes RhoC-conferred radioresistance, establishing RhoC-ROCK2 as a regulator of the DNA repair machinery.\",\n      \"method\": \"RhoC overexpression/siRNA, ROCK2 inhibition/siRNA, immunofluorescence for DNA repair markers, transcriptomic profiling, radiation survival assays, clinical sample analysis\",\n      \"journal\": \"Journal of experimental & clinical cancer research : CR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic connection via transcriptomics and immunofluorescence with functional rescue, single lab\",\n      \"pmids\": [\"31488179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"RNF180 E3 ubiquitin ligase directly binds RhoC and promotes its ubiquitination and proteasomal degradation; RhoC knockdown reduces STAT3 phosphorylation in gastric cancer cells, placing RhoC upstream of STAT3 activation.\",\n      \"method\": \"Co-immunoprecipitation for RNF180-RhoC interaction, ubiquitin label-free proteomics, RhoC shRNA knockdown, Western blot for STAT3 phosphorylation\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ubiquitination proteomics and functional phosphorylation readout, single lab\",\n      \"pmids\": [\"33082325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BCAT1 directly interacts with RhoC, elevating RhoC activity; branched-chain α-keto acids (BCKA), derived from BCAA catabolism, directly bind RhoC and promote its activity; BCAT1E61A mutation confers higher enzymatic activity and boosts RhoC-dependent cell motility; candesartan inhibits BCAT1E61A activity and represses RhoC activity.\",\n      \"method\": \"Co-immunoprecipitation of BCAT1-RhoC, in vitro BCKA-RhoC binding assay, RhoC activity assays, BCAT1 knockout/rescue with BCAT1E61A, in vitro motility assays, in vivo peritoneal metastasis model\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro direct binding of BCKA to RhoC plus Co-IP of BCAT1-RhoC complex, functional rescue and in vivo validation, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"37337119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FMNL3 interacts directly with RhoC (demonstrated by Co-IP, immunofluorescence co-localization, and GST pull-down), acts as an effector of RhoC to activate the FAK/p-MAPK/p-AKT signaling pathway, and regulates RhoC-dependent remodeling of actin-based protrusions (filopodia and lamellipodia) to promote colorectal cancer cell invasion.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence co-localization, GST pull-down assay, FAK/MAPK/AKT Western blot, pharmacological inhibitors (TAE226, U0126, LY294002), invasion/migration assays\",\n      \"journal\": \"World journal of gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — three independent protein interaction methods (Co-IP, co-localization, GST pull-down) plus pathway pharmacology, single lab\",\n      \"pmids\": [\"30228782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"RhoC regulates cancer stem cell (CSC) formation in HNSCC by promoting IL-6 secretion, which rescues STAT3 phosphorylation; RhoC knockdown decreases ALDH, CD44, and stem cell transcription factors (Nanog, Oct3/4, Sox2) and reduces STAT3 phosphorylation; IL-6 stimulation rescues STAT3 phosphorylation in RhoC knockdown lines.\",\n      \"method\": \"shRNA knockdown of RhoC, ALDH/CD44 flow cytometry, tumorsphere formation, IL-6 ELISA, Western blot for STAT3 phosphorylation, STAT3 overexpression rescue\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined epistatic pathway via IL-6/STAT3 rescue, single lab\",\n      \"pmids\": [\"24533098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Caveolin-1 overexpression mediates IBC cell invasion through activation of Akt1, which phosphorylates RhoC GTPase; caveolin-1 siRNA knockdown decreases Akt1 activation and thereby decreases RhoC phosphorylation and IBC cell invasion.\",\n      \"method\": \"caveolin-1 siRNA and scaffolding domain inhibition, Western blot for Akt1 activation and RhoC phosphorylation, invasion assays\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic KD experiments linking caveolin-1 to Akt1-RhoC phosphorylation pathway, single lab\",\n      \"pmids\": [\"25559359\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RhoC is a membrane-associated small GTPase that is activated by specific GEFs (including SmgGDS and p190RhoGEF) and inactivated by GAPs (including p190RhoGAP and ARHGAP21); it requires geranylgeranylation for membrane localization and biological activity; it acts through distinct effectors including formins FMNL2 and FMNL3, ROCK1/ROCK2, and IQGAP1 to reorganize the actin cytoskeleton, regulate cofilin phosphorylation at invadopodia, drive directional cell migration and invasion; upstream regulators include PKCε (via serine phosphorylation), Akt1 (direct phosphorylation required for invasion), p38γ (via ubiquitination control of RhoC stability), RNF180 (E3 ligase promoting RhoC degradation), and BCAT1-derived branched-chain α-keto acids (direct binding to activate RhoC); spatiotemporally, RhoC activity is confined to areas surrounding invadopodia by p190RhoGEF/p190RhoGAP, and is antagonized by the RhoD-PAK6 axis; physiologically, RhoC is dispensable for normal development but specifically required for metastasis, and also regulates angiogenic factor secretion, endothelial barrier function, cancer stem cell maintenance via IL-6/STAT3, and radioresistance via ROCK2/DNA repair machinery.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RhoC is a membrane-associated small GTPase that regulates actin cytoskeleton dynamics and is the principal Rho isoform driving tumor cell motility, invasion, and metastasis [#0, #1, #9]. Genetic ablation establishes that RhoC is dispensable for embryogenesis and tumor initiation but specifically required for metastasis, acting on tumor cell motility and metastatic cell survival [#9]. Biochemically RhoC is distinguished from RhoA by higher intrinsic GTP-binding affinity, faster exchange kinetics, and predominantly membrane localization, and its biological activity depends on geranylgeranylation for proper subcellular targeting [#5, #29]. RhoC cycling is governed by isoform-selective regulators: SmgGDS and p190RhoGEF activate it while p190RhoGAP and ARHGAP21 inactivate it, and a structural determinant (Ile43) excludes activation by the GEF XPLN [#3, #15, #19, #28]. Live-biosensor imaging shows RhoC activity is spatially confined to the rim surrounding invadopodia by reciprocal localization of p190RhoGEF and p190RhoGAP, restricting cofilin-mediated actin barbed-end generation to the invadopodium core and directing protrusion [#15, #24]. Downstream, RhoC signals through the RhoC-selective formin effectors FMNL2 and FMNL3, through ROCK1/ROCK2, and through IQGAP1 to remodel actin, control migratory polarity, and drive invasion and proliferation [#13, #16, #20, #23, #40]. Upstream, RhoC is activated or stabilized by PKCε- and Akt1-mediated phosphorylation, by p38γ-controlled ubiquitination, and by direct binding of BCAT1 and branched-chain α-keto acids, while RNF180-mediated ubiquitination targets it for degradation [#11, #17, #22, #38, #39]. Beyond cancer cell-autonomous invasion, RhoC promotes angiogenic factor secretion and MMP induction, endothelial barrier and proliferation homeostasis, cancer stem cell maintenance via IL-6/STAT3, and radioresistance via a ROCK2-DNA repair axis [#2, #7, #25, #37, #41].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Established that a Rho protein controls actin microfilament organization, the foundational activity later attributed to RhoC-driven cell shape change.\",\n      \"evidence\": \"In vitro C3 exoenzyme ADP-ribosylation of bacterially expressed RhoC plus microfilament/morphology readout in Vero cells\",\n      \"pmids\": [\"2501082\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"C3 does not distinguish RhoC from other Rho isoforms\", \"no isoform-specific effectors identified\", \"no link to invasion or metastasis yet\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Defined RhoC as a functional driver of tumor cell invasion and metastasis rather than a passive marker, and linked it to angiogenic factor production.\",\n      \"evidence\": \"Gain- and dominant-negative loss-of-function in melanoma and mammary epithelial cells with in vivo metastasis assays and ELISA for angiogenic factors\",\n      \"pmids\": [\"10952316\", \"11191108\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"dominant-negative Rho is not RhoC-selective\", \"direct effectors mediating invasion unidentified\", \"mechanism linking RhoC to angiogenic secretion unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showed that GEF activation of RhoC is isoform-selective and identified the structural determinant (Ile43) governing GEF discrimination among Rho isoforms.\",\n      \"evidence\": \"In vitro nucleotide exchange assays and site-directed mutagenesis comparing XPLN action on RhoA/B/C\",\n      \"pmids\": [\"12221096\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"did not identify the physiological RhoC GEF\", \"structural basis tested for one GEF only\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrated that RhoC requires geranylgeranylation for membrane localization and biological activity, defining a druggable post-translational dependency.\",\n      \"evidence\": \"Atorvastatin (HMG-CoA reductase) inhibition with subcellular fractionation, Rho activity assays, and in vivo metastasis of RhoC-overexpressing cells\",\n      \"pmids\": [\"14578459\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"statin effects not RhoC-specific\", \"prenylation enzymes not directly perturbed\", \"in vivo specificity for RhoC over RhoA limited\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Distinguished RhoC from RhoA functionally, showing RhoC selectively promotes invasion (not proliferation) and that RhoA/RhoC and Rac1 are reciprocally balanced.\",\n      \"evidence\": \"Selective retroviral RNAi of RhoA vs RhoC with invasion assays and Rho/Rac activity measurements; orthotopic lung model linking RhoC to MMP-2\",\n      \"pmids\": [\"15574779\", \"14871999\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"molecular basis of RhoA/RhoC antagonism unresolved at this stage\", \"effector mediating invasion not identified\", \"single cell-line systems\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Provided definitive in vivo genetics establishing RhoC as required for metastasis but dispensable for development and tumor initiation.\",\n      \"evidence\": \"RhoC knockout mouse with tumor induction, motility, survival, and metastasis quantification\",\n      \"pmids\": [\"16107613\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"does not define the effector pathway responsible in vivo\", \"potential compensation by RhoA not fully excluded\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Dissected the downstream signaling branches, separating RhoC-driven invasion (ROCK-independent PI3K/Akt and FAK/MAPK) from random motility and from anchorage-independent growth.\",\n      \"evidence\": \"Pharmacological pathway dissection and dominant-negative/C3 inhibition in melanoma and prostate cancer cells with invasion/motility readouts\",\n      \"pmids\": [\"16470169\", \"16314838\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"pharmacological inhibitors lack isoform selectivity\", \"direct RhoC-effector contacts not demonstrated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified RhoC-selective formin effectors (FMNL2, FMNL3) and isoform-specific roles in integrin regulation and endothelial homeostasis, explaining RhoC's distinct cytoskeletal output.\",\n      \"evidence\": \"siRNA formin screen with selective active-GTPase pulldowns and 3D invasion epistasis; isoform-selective RNAi for integrin surface expression; HUVEC and zebrafish endothelial assays\",\n      \"pmids\": [\"20101212\", \"20503409\", \"26136364\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"structural basis of FMNL2/3 selectivity for RhoC not resolved\", \"endothelial mechanisms from single lab\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Resolved the spatial control of RhoC at invadopodia and defined its dedicated GEF/GAP pair, plus ROCK1/2 and FMNL3 partitioning of migratory polarity.\",\n      \"evidence\": \"RhoC FLARE biosensor live imaging with p190RhoGEF/p190RhoGAP localization and cofilin phosphorylation readouts; reciprocal RNAi with FMNL3/ROCK epistasis\",\n      \"pmids\": [\"21474314\", \"21576392\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"recruitment mechanism positioning p190RhoGEF vs p190RhoGAP unresolved\", \"biosensor used in limited cell types\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established additional isoform-selective regulators and effectors—SmgGDS as a RhoA/RhoC-specific activator, PKN3 and IQGAP1 as preferential RhoC partners, and PKCε/p38γ/RhoGDIα as upstream controllers of RhoC activity and stability.\",\n      \"evidence\": \"In vitro exchange assays across a large GTPase panel with mutagenesis; Co-IP and in vitro kinase assays; RNAi/rescue epistasis and ubiquitination assays\",\n      \"pmids\": [\"21242305\", \"22217540\", \"21537845\", \"17018591\", \"21862636\", \"21757538\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"several interactions rest on single Co-IP studies\", \"direct PKCε phosphorylation of RhoC inferred not proven\", \"in vivo relevance of each axis variable\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrated direct Akt1 phosphorylation of RhoC as essential for inflammatory breast cancer invasion, and confirmed IQGAP1 as a proliferative effector, linking specific kinase inputs to RhoC output.\",\n      \"evidence\": \"In vitro Akt1 kinase assay with phospho-specific detection and isoform-selective siRNA rescue; Co-IP and proliferation assays for IQGAP1\",\n      \"pmids\": [\"22896661\", \"23145020\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"phosphosite consequences on GTPase cycle not structurally defined\", \"clinical correlation from single cohort\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Quantified RhoC biochemical distinctiveness and effector binding (PRK/PKN affinities, ARHGAP21 GAP activity) and refined spatiotemporal models of RhoC vs RhoA during protrusion.\",\n      \"evidence\": \"In vitro binding/affinity assays, GAP activity assays, and FRET biosensor live imaging with computational analysis\",\n      \"pmids\": [\"24128008\", \"23200924\", \"24224016\", \"23704350\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"functional consequence of PRK affinity differences in cells untested\", \"GAP studies from single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Placed RhoC within transcriptional/microenvironmental regulatory networks, with HIF-3α, Notch1, p53, and miRNAs (miR-10b, miR-493) controlling RhoC expression or RhoC-ROCK1 signaling.\",\n      \"evidence\": \"Transcriptional reporter/ChIP assays, miRNA 3'UTR luciferase and Co-IP, and pharmacological/genetic interventions with invasion readouts\",\n      \"pmids\": [\"28928287\", \"19953094\", \"21079653\", \"20843787\", \"22057916\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"several transcriptional links inferred from reporter assays\", \"context-dependence across tumor types not reconciled\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined antagonistic and degradative control of RhoC—the RhoD-PAK6 axis suppressing RhoC-dependent contraction, RNF180 driving RhoC degradation, and ROCK-mediated endothelial transmigration—expanding the regulatory and effector network.\",\n      \"evidence\": \"Genetic epistasis in viral infection and normal cells, Co-IP plus ubiquitination proteomics, and RNAi cancer-endothelial interaction assays\",\n      \"pmids\": [\"28486133\", \"33082325\", \"25677806\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"RNF180 link rests on single-lab Co-IP/proteomics\", \"physiological setting for RhoD-PAK6 antagonism beyond viral context limited\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Connected RhoC to metabolism, showing BCAT1 and branched-chain α-keto acids directly bind and activate RhoC to promote motility, defining a metabolite-driven activation mode.\",\n      \"evidence\": \"Co-IP of BCAT1-RhoC, in vitro BCKA-RhoC binding, activity assays, BCAT1E61A rescue, and in vivo peritoneal metastasis model\",\n      \"pmids\": [\"37337119\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"binding site of BCKA on RhoC not structurally mapped\", \"single-lab in vivo validation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the many isoform-selective regulators and effectors are integrated spatiotemporally in vivo, and the structural basis distinguishing RhoC from RhoA at the effector/regulator interface, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"no high-resolution structure of RhoC with its selective GEFs/GAPs/effectors\", \"lack of in vivo causal ordering of the upstream kinase/metabolite/ubiquitin inputs\", \"redundancy and compensation with RhoA not fully separated genetically\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003924\", \"supporting_discovery_ids\": [3, 19, 28, 29]},\n      {\"term_id\": \"GO:0005525\", \"supporting_discovery_ids\": [29]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [13, 16, 35]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [5, 29]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [0, 15]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [29]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [12, 15, 22]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 9]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"FMNL2\", \"FMNL3\", \"IQGAP1\", \"ROCK1\", \"ROCK2\", \"PKN3\", \"SmgGDS\", \"BCAT1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}